What Is Endomorphin-1? Definition and What Research Reports

Definition

Endomorphin-1 is an endogenous opioid tetrapeptide with the sequence Tyr-Pro-Trp-Phe-NH₂. It was identified in mammalian brain tissue and is described in the literature as one of the most selective naturally occurring ligands for the mu-opioid receptor (MOR), the same receptor family targeted by morphine and related alkaloids. Along with its close relative endomorphin-2 (Tyr-Pro-Phe-Phe-NH₂), it is classified as a short amidated peptide rather than a protein or a synthetic small molecule. In peptide research the term "endomorphin-1" is used both for the native peptide and, loosely, as the parent scaffold for a large family of chemically modified analogs designed to resist enzymatic breakdown or to cross the blood–brain barrier more readily.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or a specific compound. Endomorphin-1 is not an approved drug product in the United States; it appears in the scientific record as a laboratory reagent and preclinical research subject.

Molecule Class and Origin

Endomorphin-1 belongs to the endogenous opioid peptide class, which also includes the enkephalins, beta-endorphin and the dynorphins. Unlike those families, the endomorphins are only four amino acids long and carry a C-terminal amide, and they do not share the classic Tyr-Gly-Gly-Phe opioid motif. The precursor gene for the endomorphins has remained a point of discussion in the field; the peptides themselves have been detected immunohistochemically in nervous tissue and, in one report, outside the nervous system.

Distribution work has mapped where the peptide can be detected. A 2024 immunohistochemical study examined endomorphin-1 in rat cranial sensory ganglia and reported its presence in sensory neurons together with an anti-nociceptive function in that system (PMID 38556265). Separately, a 2004 study reported immunohistochemical staining for endomorphin-1 and endomorphin-2 in immune cells of the spleen, indicating detection of the peptides outside classical neural tissue (PMID 15003360).

How the Term Is Used in Peptide Research

In published work, "endomorphin-1" generally appears in one of four contexts:

• As a receptor probe. Because of its mu-opioid selectivity, it is used to interrogate MOR structure, binding sites and downstream signalling.
• As an antinociceptive test agent. Rodent pain models use it to characterise spinal and supraspinal opioid analgesia.
• As a chemical scaffold. Medicinal chemistry groups build glycosylated, cyclised or amphiphilic analogs on the endomorphin-1 backbone.
• As a comparator for opioid liabilities. Studies compare it with morphine on tolerance, dependence and withdrawal endpoints.

Receptor pharmacology

An antisense oligonucleotide study set out to identify the endomorphin-1 and endomorphin-2 binding sites within the human mu-opioid receptor, reporting which receptor regions contributed to peptide binding (PMID 19090917). A 2020 pharmacology paper reported that endomorphin-1, endomorphin-2 and dynorphin-B displayed biased agonism at the mu-opioid receptor — that is, the peptides did not activate G-protein and beta-arrestin pathways in the same proportion as reference agonists (PMID 32112361). Biased agonism is a recurring theme in opioid peptide research because signalling pathway preference has been proposed as one variable distinguishing analgesic from non-analgesic effects.

What the Published Literature Reports

Antinociception in animal models

A 2001 report in Acta Pharmacologica Sinica described the analgesic effect of endomorphin-1 in animal testing (PMID 11749786). The 2024 rat cranial sensory ganglia study likewise reported an anti-nociceptive function attributable to endogenous endomorphin-1 in craniofacial sensory pathways (PMID 38556265).

Spinal cord electrophysiology

Researchers recording from adult rat substantia gelatinosa neurons — the superficial dorsal horn layer where nociceptive input is processed — reported that endomorphin-1 and endomorphin-2 inhibited excitatory synaptic transmission in those neurons (PMID 16515840). This kind of finding is often cited as a cellular correlate of the behavioural antinociception seen in whole-animal work.

Analogs and delivery chemistry

Because the native tetrapeptide is rapidly degraded and penetrates the brain poorly, much of the modern literature concerns derivatives. A 2024 study reported that cyclic glycopeptide analogs of endomorphin-1 produced highly effective antinociception in both male and female mice (PMID 39411536). A 2019 report described an amphiphilic endomorphin-1 derivative that self-assembled into a nanomedicine format for brain delivery (PMID 31474737). A 2020 Journal of Neurochemistry paper reported that an endomorphin analog alleviated neuropathic hyperalgesia and attributed part of its profile to weak activation of NMDA receptors (PMID 32666510).

Other reported activities

A 2016 study in a rat endometriosis model examined endomorphin-1 and the mu-opioid receptor and discussed their role and significance in that condition (PMID 27252115). A separate line of work evaluated endomorphin-1 for effects on Na⁺,K⁺-ATPase activity using both in vitro and in vivo approaches (PMID 12504785).

Reported Liabilities: What Studies Report

Endomorphin-1 is a mu-opioid agonist, and the literature has examined whether it carries the dependence liability associated with that receptor. A 2003 study in Peptides reported that endomorphin-1 and endomorphin-2 induced naloxone-precipitated withdrawal syndromes in rats, indicating that repeated administration produced a dependent state reversible by opioid antagonism (PMID 12732348). Researchers investigating analog chemistry have framed reduced tolerance and dependence as a design goal; the 2020 neuropathic hyperalgesia paper reported an analog profile involving weak NMDA receptor activation in that context (PMID 32666510). Human safety data for endomorphin-1 are not established in the papers summarised here, and nothing on this page describes administration in people.

Quick Reference Table

Limits of the Evidence

The evidence base summarised here is preclinical. It consists of rodent behavioural models, ex vivo electrophysiology, immunohistochemistry and receptor-level pharmacology. Findings in those systems do not establish what would happen in humans, and the analog studies describe modified molecules rather than the native peptide. Readers comparing endomorphin-1 to other opioid peptides should note that differences in route, species, model and the specific analog tested make direct comparison across papers difficult. Any clinical question belongs with a licensed physician.

References

• Distribution and anti-nociceptive function of endomorphin-1 in the rat cranial sensory ganglia (Biomedical Research, 2024)
• The role and significance of endomorphin-1 and μ-opioid receptor in rats with endometriosis (Gynecological Endocrinology, 2016)
• The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor (Pharmacological Reports, 2020)
• Cyclic Glycopeptide Analogs of Endomorphin-1 Provide Highly Effective Antinociception in Male and Female Mice (ACS Medicinal Chemistry Letters, 2024)
• Endomorphin-1 and -2 induce naloxone-precipitated withdrawal syndromes in rats (Peptides, 2003)
• Amphiphilic Endomorphin-1 Derivative Functions as Self-assembling Nanomedicine for Effective Brain Delivery (Chemical & Pharmaceutical Bulletin, 2019)
• Analgesic effect of endomorphin-1 (Acta Pharmacologica Sinica, 2001)
• Immunohistochemical staining of endomorphin 1 and 2 in the immune cells of the spleen (Peptides, 2004)
• Identification of endomorphin-1 and endomorphin-2 binding sites in human mu-opioid receptor by antisense oligonucleotide strategy (Chemical Biology & Drug Design, 2008)
• Endomorphin analog exhibited superiority in alleviating neuropathic hyperalgesia via weak activation of NMDA receptors (Journal of Neurochemistry, 2020)
• Inhibition by endomorphin-1 and endomorphin-2 of excitatory transmission in adult rat substantia gelatinosa neurons (Neuroscience, 2006)
• Evaluation of endomorphin-1 on the activity of Na(+),K(+)-ATPase using in vitro and in vivo studies (European Journal of Pharmacology, 2003)